EMARegulatory
New medicine to reduce triglycerides in adults with familial chylomicronaemia syndrome
Summary
EMA has recommended granting a marketing authorisation in the European Union (EU) for Redemplo (plozasiran) to treat adults with familial chylomicronaemia syndrome (FCS).FCS is…
EMA has recommended granting a marketing authorisation in the European Union (EU) for Redemplo (plozasiran) to treat adults with familial chylomicronaemia syndrome (FCS).FCS is…